Key result
The 2-phenoxy-3-pyridylurea analog 18 demonstrated improved antiischemic potency and cardiac selectivity compared to the benzopyran-based lead compound 4.
The benzopyran ring is not mandatory for the antiischemic activity and cardiac selectivity of KATP openers, allowing for structurally simpler acyclic analogs.
No takes yet. Share an insight, caveat, or question.
May enable simpler KATP opener designs for ischemia; hypothesis-generating in animal models, clinical translation unknown.
Atwal et al. (1996) studied Ischemia. Acyclic analogs (e.g., 2-phenoxy-3-pyridylurea analog 18) vs. Benzopyran-based compound 4 was evaluated on Antiischemic potency and selectivity. The 2-phenoxy-3-pyridylurea analog 18 demonstrated improved antiischemic potency and cardiac selectivity compared to the benzopyran-based lead compound 4.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: